Is Turning Point Brands Stock a Buy After Investment Firm Cannell Capital Raises Its Stake to Nearly $20 Million?

Cannell Capital substantially increased its position in Turning Point Brands (NYSE:TPB) during Q3, acquiring an additional 119,821 shares to bring its total holding to 180,100 shares valued at $17.80 million, representing 2.7% of its assets under management. This increased stake follows TPB's strong Q3 results, which included a 31% year-over-year sales increase to $119 million and a 70% rise in net income to $21 million, largely propelled by a 628% surge in its Modern Oral product line, prompting a significant upward revision of its 2025 Modern Oral sales forecast. The move suggests Cannell Capital's conviction in TPB's growth trajectory, despite the stock's rising price-to-earnings ratio after a 75% gain over the past year.

Analysis

Cannell Capital significantly increased its position in Turning Point Brands (TPB) during Q3 2025, adding 119,821 shares to reach a total of 180,100 shares valued at $17.80 million. This elevated TPB to 2.71% of Cannell's reportable assets under management, up from 1.4% in Q2, signaling strong institutional conviction.

This increased stake aligns with TPB's robust Q3 performance, which saw sales rise 31% year-over-year to $119 million and net income jump 70% to $21 million, resulting in diluted EPS of $1.13. A key driver was the Modern Oral nicotine pouch line, experiencing a 628% sales surge to $37 million in Q3.

The exceptional growth prompted TPB to significantly raise its 2025 Modern Oral sales forecast to $125-$130 million, a substantial increase from the initial $60-$80 million guidance. The stock has responded positively, trading at $101.22 as of November 14, 2025, after a 75% gain over the past year.

Despite strong operational performance and positive market reaction, the article highlights a steadily increasing price-to-earnings ratio throughout 2025. This suggests that while fundamentals are robust, valuation concerns may warrant a cautious approach for new entries at current levels.

Key Decisions for Investors

• Investors should closely monitor the continued growth trajectory of TPB's Modern Oral product line, as its exceptional performance is a primary driver of the company's revised outlook.
• Given the stock's 75% year-over-year appreciation and rising P/E ratio, it may be prudent to evaluate current valuation levels and consider potential entry points during any market pullbacks.
• Assess the sustainability of TPB's diversified product strategy and its ability to maintain competitive advantages within the evolving tobacco and alternative products sector.